Dapagliflozin

Generic Name
Dapagliflozin
Brand Names
Edistride, Farxiga, Forxiga, Qtern, Qternmet, Xigduo, Dapagliflozin Viatris
Drug Type
Small Molecule
Chemical Formula
C21H25ClO6
CAS Number
461432-26-8
Unique Ingredient Identifier
1ULL0QJ8UC
Background

Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and it was the first SLGT2 inhibitor to be approved. indicated for managing diabetes mellitus type 2. When combined with diet and exercise in adults, dapagliflozin helps to improve glycemic control by inhibiting glucose reabsorption in the proximal tubule of the nephron and causing glycosur...

Indication

Dapagliflozin is indicated as an adjunct treatment to improve glycemic control in adult patients with type 2 diabetes mellitus along with diet and exercise.For patients with chronic kidney disease at risk of progression, dapagliflozin in used to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, and
...

Associated Conditions
Cardiovascular Mortality, End Stage Renal Disease (ESRD), Hospitalizations, Type 2 Diabetes Mellitus, Decreased estimated glomerular filtration rate, Hospitalization due to cardiac failure
Associated Therapies
-
Clinical Trials
Related News

Study of Safety and Efficacy of Dapagliflozin + Metformin XR Versus Metformin XR in Participants With HR+, HER2-, Advanced Breast Cancer While on Treatment With Alpelisib and Fulvestrant

First Posted Date
2021-05-24
Last Posted Date
2024-10-09
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
2
Registration Number
NCT04899349
Locations
🇺🇸

Washington Uni School of Med Siteman Cancer Center, Saint Louis, Missouri, United States

🇲🇾

Novartis Investigative Site, Kuala Lumpur, Malaysia

Neoadjuvant SGLT2 Inhibition in High-Risk Localized Prostate Cancer

Phase 1
Recruiting
Conditions
Prostate Cancer
Cancer of Prostate
Interventions
Drug: Dapagliflozin
First Posted Date
2021-05-14
Last Posted Date
2024-10-02
Lead Sponsor
Washington University School of Medicine
Target Recruit Count
24
Registration Number
NCT04887935
Locations
🇺🇸

Washington University School of Medicine, Saint Louis, Missouri, United States

Replication of the DAPA-CKD (Chronic Kidney Disease) Trial in Healthcare Claims Data

First Posted Date
2021-05-12
Last Posted Date
2023-07-28
Lead Sponsor
Brigham and Women's Hospital
Target Recruit Count
87727
Registration Number
NCT04882813
Locations
🇺🇸

Brigham and Women's Hospital, Boston, Massachusetts, United States

Dapagliflozin on Volume Vascular Outcomes.

Phase 4
Completed
Conditions
Heart Failure，Congestive
Interventions
Drug: Dapagliflozin
Drug: Placebo
First Posted Date
2021-05-03
Last Posted Date
2024-11-12
Lead Sponsor
Frank Ruschitzka
Target Recruit Count
80
Registration Number
NCT04869124
Locations
🇨🇭

University Heart Center Zurich, Zurich, Switzerland

Clinical Trial to Evaluate Pharmacokinetic Interaction of ATB-1011 and ATB-1012 in Healthy Adult Volunteers

First Posted Date
2021-04-23
Last Posted Date
2021-09-05
Lead Sponsor
Autotelicbio
Target Recruit Count
38
Registration Number
NCT04856969
Locations
🇰🇷

H Plus Yangji Hospital, Seoul, Gwanak-gu, Korea, Republic of

The Effect of Sodium-glucose Cotransporter (SGLT) 2 Inhibitors on Cystine Stone Formation: A Preliminary Study

Phase 2
Recruiting
Conditions
Cystinuria
Interventions
Drug: Dapagliflozin
First Posted Date
2021-03-26
Last Posted Date
2023-08-14
Lead Sponsor
University of California, San Francisco
Target Recruit Count
10
Registration Number
NCT04818034
Locations
🇺🇸

University of California, San Francisco, San Francisco, California, United States

GliflOzin in eLderly Diabetic patiENts: A praGmatic Intraclass Evaluation Trial

First Posted Date
2021-03-12
Last Posted Date
2021-03-12
Lead Sponsor
Center for Outcomes Research and Clinical Epidemiology, Italy
Target Recruit Count
1167
Registration Number
NCT04796428

Use of Dapagliflozin to Reduce Burden of Atrial Fibrillation in Patients Undergoing Catheter Ablation of Symptomatic Atrial Fibrillation

Phase 4
Completed
Conditions
Atrial Fibrillation
Interventions
Drug: Placebo
Drug: dapagliflozin
First Posted Date
2021-03-10
Last Posted Date
2024-12-04
Lead Sponsor
University of Rochester
Target Recruit Count
25
Registration Number
NCT04792190
Locations
🇺🇸

Maine Medical Center, Portland, Maine, United States

🇺🇸

Henry Ford Hospital, Detroit, Michigan, United States

🇺🇸

University of Rochester Medical Center, Rochester, New York, United States

Effect of Dapagliflozin on LV Remodeling Post AMI

Phase 4
Recruiting
Conditions
Myocardial Infarction
Interventions
Drug: Placebo
Drug: Dapagliflozin
First Posted Date
2021-03-05
Last Posted Date
2021-03-05
Lead Sponsor
Instituto Mexicano del Seguro Social
Target Recruit Count
60
Registration Number
NCT04783870
Locations
🇲🇽

Hospital de Cardiología, Centro Médico Nacional Siglo XXI, Ciudad de México, Mexico

Dapagliflozin to Prevent Atrial Fibrillation Recurrence After Transcatheter Pulmonary Venous Isolation.

First Posted Date
2021-03-03
Last Posted Date
2021-07-27
Lead Sponsor
G.Gennimatas General Hospital
Target Recruit Count
350
Registration Number
NCT04780438
Locations
🇬🇷

Cardiology Department, Athens General Hospital "G. Gennimatas", Athens, Greece, Athens, Greece

🇬🇷

2nd Department of Cardiology, National and Kapodistrian University of Athens, Faculty of Medicine, Athens, Greece., Athens, Greece

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy